Mineralys Therapeutics (MLYS) Accumulated Expenses (2022 - 2026)
Quarterly results put Accumulated Expenses at $13.6 million for Q1 2026, up 4.53% from a year ago — trailing twelve months through Mar 2026 was $13.6 million (up 4.53% YoY), and the annual figure for FY2025 was $13.1 million, down 7.56%.
Mineralys Therapeutics has reported Accumulated Expenses over the past 5 years, most recently at $13.6 million for Q1 2026.
- Accumulated Expenses reached $13.6 million in Q1 2026 per MLYS's latest filing, up from $13.1 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $28.2 million in Q3 2024 and bottomed at $4.0 million in Q2 2023.
- Median Accumulated Expenses over the past 5 years was $13.3 million (2025), compared with a mean of $14.4 million.
- The largest annual shift saw Accumulated Expenses surged 565.42% in 2024 before it dropped 28.78% in 2025.
- Over 5 years, Accumulated Expenses stood at $6.2 million in 2022, then skyrocketed by 60.41% to $9.9 million in 2023, then soared by 43.38% to $14.2 million in 2024, then dropped by 7.56% to $13.1 million in 2025, then grew by 3.86% to $13.6 million in 2026.
- Business Quant data shows Accumulated Expenses for MLYS at $13.6 million in Q1 2026, $13.1 million in Q4 2025, and $22.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Mineralys Therapeutics | 2.50 Bn | 2.50 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.60 Mn |
| Dec 31, 2025 | 13.10 Mn |
| Sep 30, 2025 | 22.40 Mn |
| Jun 30, 2025 | 19.01 Mn |
| Mar 31, 2025 | 13.01 Mn |
| Dec 31, 2024 | 14.17 Mn |
| Sep 30, 2024 | 28.22 Mn |
| Jun 30, 2024 | 26.69 Mn |
| Mar 31, 2024 | 14.94 Mn |
| Dec 31, 2023 | 9.88 Mn |
| Sep 30, 2023 | 7.97 Mn |
| Jun 30, 2023 | 4.01 Mn |
| Mar 31, 2023 | 8.17 Mn |
| Dec 31, 2022 | 6.16 Mn |